Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.73 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.72 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.71 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.69 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.66 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.60 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30412034 | 1.00 | MAOB (0.73) | MAOBNR4A2MRGPRX4SMPD1PTPN1 | |
| SCHEMBL1122805 | 0.97 | MRGPRX4 (0.71) | MAOBNR4A2MRGPRX4SMPD1PTPN1 | |
| SCHEMBL1122722 | 0.96 | MAOB (0.68) | MAOBNR4A2MRGPRX4SMPD1PTPN1 | |
| SCHEMBL10411878 | 0.92 | MRGPRX4 (0.77) | MAOBNR4A2MRGPRX4SMPD1CYSLTR1 | |
| SCHEMBL1171850 | 0.92 | MRGPRX4 (0.65) | MAOBNR4A2MRGPRX4SMPD1PTPN1 | |
| SCHEMBL28768851 | 0.89 | MAOB (0.58) | MAOBNR4A2MRGPRX4SMPD1PTPN1 | |
| SCHEMBL2254423 | 0.88 | SMPD1 (0.76) | MAOBNR4A2MRGPRX4SMPD1LMNA | |
| SCHEMBL2654709 | 0.88 | MRGPRX4 (0.71) | MAOBNR4A2MRGPRX4SMPD1CYSLTR1 | |
| SCHEMBL391547 | 0.88 | MEN1 (0.71) | MAOBNR4A2MRGPRX4SMPD1PTPN1 | |
| SCHEMBL183994 | 0.88 | LMNA (0.70) | MAOBNR4A2MRGPRX4SMPD1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | claimed |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | NOVO NORDISK A/S (DK) | 2009-05-28 | — | — | US | claimed |
| US-20070270408-A1 | Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines | NOVO NORDISK A/S (DK) | 2007-11-22 | — | — | US | claimed |
| EP-1782859-A2 | Pharmaceutical use of substituted pyrazolo [1,5- a]pyrimidines | NOVO NORDISK A/S (DK) | 2007-05-09 | — | — | EP | claimed |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HIGH POINT PHARMACEUTICALS, LLC | 2006-05-04 | — | — | US | claimed |
| EP-1615666-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | claimed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| US-12600703-B2 | Methods of synthesizing farnesyl dibenzodiazepinones | AMO PHARMA LTD. (GB) | 2026-04-14 | — | — | US | disclosed |
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-20 | — | — | US | disclosed |
| US-20240317730-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-09-26 | — | — | US | disclosed |
| US-20240262815-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOI INC (KR) | 2024-08-08 | — | — | US | disclosed |
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| EP-0049953-B1 | 4-(SUBSTITUTED PHENYL)-NAPHTHALEN-2(1H)-ONES AND 2-OLS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER INC. (US) | 1984-05-16 | — | — | EP | disclosed |
| EP-0079168-A1 | Process for making 1-(3-benzyloxyphenyl)-1,1-dimethylheptane and intermediates therefor | PFIZER INC. (US) | 1983-05-18 | — | — | EP | disclosed |
| US-4360700-A | Intermediates for making 1-(3-benzyloxyphenyl)-1,1-dimethylheptane | PFIZER INC. (US) | 1982-11-23 | — | — | US | disclosed |
| US-4331602-A | CNS AGENTS, ANTIEMETICS, ANTIDIARRHEA | PFIZER INC. (US) | 1982-05-25 | — | — | US | disclosed |
| EP-0049953-A2 | 4-(Substituted phenyl)-naphthalen-2(1H)-ones and 2-ols, processes for their preparation, and pharmaceutical compositions containing them | PFIZER INC. (US) | 1982-04-21 | — | — | EP | disclosed |
| US-4285867-A | ANTIDIARRHEA AGENTS, ANTIEMETICS, ANALGESICS | PFIZER INC. (US) | 1981-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | MAOB 1885/4885NR4A2 1988/4885MRGPRX4 2888/4885 |
| US-20070270408-A1 | Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines | HSD3B1, HSD11B1, SRD5A1 | MAOB 1128/4885NR4A2 1656/4885MRGPRX4 1293/4885 |
| US-20060094699-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy | HSD11B1, HSD17B1, NR3C1 | MAOB 2397/4885NR4A2 129/4885MRGPRX4 334/4885 |
| US-20090137574-A1 | Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and Disorders | HSD11B1, HSD11B2, HSD17B1 | MAOB 599/4885NR4A2 2025/4885MRGPRX4 2259/4885 |
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | HSD11B1, HSD11B2, HSD17B1 | MAOB 599/4885NR4A2 2025/4885MRGPRX4 2259/4885 |
| US-20240262815-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | ERBB2, ERBB4, ERBB3 | MAOB 3672/4885NR4A2 152/4885MRGPRX4 2406/4885 |
| US-20240317730-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | ERBB2, EGFR, ERBB3 | MAOB 1885/4885NR4A2 1988/4885MRGPRX4 2888/4885 |
| US-20090264412-A1 | Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy | HSD11B1, HSD17B1, NR3C1 | MAOB 2397/4885NR4A2 129/4885MRGPRX4 334/4885 |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | MAOB 3077/4885NR4A2 267/4885MRGPRX4 903/4885 |
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | MAOB 2014/4885NR4A2 2421/4885MRGPRX4 2466/4885 |
| US-12600703-B2 | Methods of synthesizing farnesyl dibenzodiazepinones | NR1H2, NR1H3, NR1H4 | MAOB 2969/4885NR4A2 715/4885MRGPRX4 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.